SG10202105186XA - Methods for treating multiple osteochondroma (mo) - Google Patents

Methods for treating multiple osteochondroma (mo)

Info

Publication number
SG10202105186XA
SG10202105186XA SG10202105186XA SG10202105186XA SG10202105186XA SG 10202105186X A SG10202105186X A SG 10202105186XA SG 10202105186X A SG10202105186X A SG 10202105186XA SG 10202105186X A SG10202105186X A SG 10202105186XA SG 10202105186X A SG10202105186X A SG 10202105186XA
Authority
SG
Singapore
Prior art keywords
methods
treating multiple
multiple osteochondroma
osteochondroma
treating
Prior art date
Application number
SG10202105186XA
Inventor
Isabelle Lemire
Michael Harvey
Donna Roy Grogan
Clarissa Desjardins
Original Assignee
Clementia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clementia Pharmaceuticals Inc filed Critical Clementia Pharmaceuticals Inc
Publication of SG10202105186XA publication Critical patent/SG10202105186XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
SG10202105186XA 2016-11-16 2017-11-16 Methods for treating multiple osteochondroma (mo) SG10202105186XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662423019P 2016-11-16 2016-11-16

Publications (1)

Publication Number Publication Date
SG10202105186XA true SG10202105186XA (en) 2021-06-29

Family

ID=62144988

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202105186XA SG10202105186XA (en) 2016-11-16 2017-11-16 Methods for treating multiple osteochondroma (mo)

Country Status (14)

Country Link
US (1) US10980778B2 (en)
EP (1) EP3541380B1 (en)
JP (1) JP7018957B2 (en)
KR (1) KR20190100187A (en)
CN (1) CN110381939B (en)
AU (1) AU2017359673B2 (en)
BR (1) BR112019009929A2 (en)
CA (1) CA3043807A1 (en)
EA (1) EA039050B1 (en)
ES (1) ES2907696T3 (en)
IL (1) IL266605A (en)
MX (1) MX2019005700A (en)
SG (1) SG10202105186XA (en)
WO (1) WO2018090137A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021249240A1 (en) * 2020-06-11 2021-12-16 养生堂有限公司 Use of palovarotene in treatment against hbv virus

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20030125252A1 (en) 2000-03-14 2003-07-03 Underhill T. Michael Compositions and methods for affecting osteogenesis
JP4118675B2 (en) * 2000-10-02 2008-07-16 エフ．ホフマン−ラ ロシュ アーゲー A new retinoid for the treatment of emphysema
JP4410562B2 (en) 2001-09-18 2010-02-03 エフ．ホフマン−ラ ロシュ アーゲー Substituted urea retinoid agonist II
CN1283621C (en) 2001-09-18 2006-11-08 霍夫曼-拉罗奇有限公司 Alkyl urea vitamin A protagonist I
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (en) 2004-01-23 2005-08-04 Yasuyoshi Uchida Muscle-regenerating agent
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
KR20070121758A (en) 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 Injectable compositions of nanoparticulate immunosuppressive compounds
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
WO2007037188A1 (en) 2005-09-27 2007-04-05 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by increase in vasopermeability
MX2008012358A (en) * 2006-03-31 2008-10-09 Hoffmann La Roche Process for preparing retinoid compounds.
ES2702128T3 (en) 2006-05-16 2019-02-27 Io Therapeutics Llc Antagonist or reverse RAR agonist for use in the treatment of side effects of chemotherapy and / or radiation therapy
WO2008055072A2 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
WO2009114180A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
EP2379174A4 (en) 2008-12-18 2012-11-14 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
US20120121546A1 (en) 2009-02-05 2012-05-17 Vishal Bhasin Method of Producing Progenitor Cells from Differentiated Cells
US20120277156A1 (en) 2009-07-21 2012-11-01 University Of Washington Trhough It's Center For Commercialization Inhibition of pathological bone formation
MX361414B (en) 2010-09-01 2018-12-05 Univ Jefferson Composition and method for muscle repair and regeneration.
WO2012047674A2 (en) 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
US10485780B2 (en) * 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
EP2726084A1 (en) 2011-07-01 2014-05-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Method of treating pathologic heterotopic ossification
MX363111B (en) 2012-11-08 2019-03-08 Univ Yamaguchi Therapeutic agent for keratoconjunctive disorders.
US20160115167A1 (en) 2013-03-04 2016-04-28 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
JP6542192B2 (en) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． BMP inhibitors and methods of use thereof
CA2913005C (en) * 2013-05-22 2021-08-10 Yamaguchi University Inhibitor for retinochoroidal disorders
US20170305883A1 (en) 2014-10-01 2017-10-26 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting BMP
US20180311356A1 (en) 2015-10-19 2018-11-01 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
EP3393474B1 (en) 2015-12-24 2023-07-19 The Regents of The University of Michigan Method of treating heterotopic ossification
KR102486607B1 (en) 2016-06-08 2023-01-11 클레멘티아 파마슈티컬즈, 인크. How to treat heterotopic ossification

Also Published As

Publication number Publication date
BR112019009929A2 (en) 2019-08-20
EP3541380B1 (en) 2021-12-15
AU2017359673A1 (en) 2019-06-27
IL266605A (en) 2019-07-31
CN110381939A (en) 2019-10-25
CA3043807A1 (en) 2018-05-24
JP2019534336A (en) 2019-11-28
US20190275005A1 (en) 2019-09-12
WO2018090137A1 (en) 2018-05-24
AU2017359673B2 (en) 2021-10-21
JP7018957B2 (en) 2022-02-14
MX2019005700A (en) 2020-01-21
EA039050B1 (en) 2021-11-26
ES2907696T3 (en) 2022-04-26
EP3541380A4 (en) 2020-12-09
US10980778B2 (en) 2021-04-20
CN110381939B (en) 2022-12-02
EA201991208A1 (en) 2019-10-31
EP3541380A1 (en) 2019-09-25
KR20190100187A (en) 2019-08-28

Similar Documents

Publication Publication Date Title
EP3500289A4 (en) Methods for treating tracheobronchomalacia
PL2997550T3 (en) Method for controlling access
IL279308A (en) Methods for treating hepcidin-mediated disorders
EP3171878A4 (en) Methods for treating paramyxoviruses
HK1244217A1 (en) Methods for treating proteinopathies
EP3193865A4 (en) Methods for treating brain metastasis
HK1255871A1 (en) Cerdulatinib for treating myeloma
EP3542829A4 (en) Apparatus for treating clothing
HK1255481A1 (en) Methods for treating hcv
HK1250649A1 (en) Anti-s100a8 for treating leukemia
HK1248133A1 (en) Methods for treating neuroblastoma
EP3507838C0 (en) Device for treating parts
EP3244914A4 (en) Methods for treating tauopathy
ZA201708386B (en) Treatment for multiple myeloma (mm)
PT3426237T (en) Method for treating brain atrophy
EP3148307B8 (en) Method for treating seeds
IL266605A (en) Methods for treating multiple osteochondroma (mo)
EP3131904A4 (en) Methods for treating hypersomnia
EP3130586A4 (en) Process for treating homoserine-based compound
HK1257072A1 (en) Method for treating multiple sclerosis
IL249616A0 (en) Methods for treating infections
EP3313398A4 (en) Methods for treating hcv
EP3246432A4 (en) Method for treating parts
HK1256371A1 (en) Methods for treating tumours
AU2015904922A0 (en) Methods for treating pelvic triphosis